Research News

Zoledronic acid prevents fractures in men with osteoporosis

BMJ 2012; 345 doi: (Published 06 November 2012) Cite this as: BMJ 2012;345:e7471

OpenUrlCrossRefPubMedWeb of Science

Zoledronic acid, a bisphosphonate given intravenously at a dose of 5 mg once a year, may reduce the risk of morphometric vertebral fractures in men by 67% compared with placebo. Morphometric fractures are identified by a change in shape of a bone, rather than from pain or other symptoms. About 40% of osteoporotic fractures in people over …

View Full Text

Log in

Log in through your institution


* For online subscription